Novel Non-Absorbed Therapeutics

COMPANY OVERVIEW IN THE NEWS

Relypsa is a clinical-stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate, RLY5016, is a non- absorbed potassium binder for the treatment of hyperkalemia and is currently being tested in a pivotal phase 3 clinical study. Relypsa is pursuing the discovery of additional product candidates through use of its proprietary polymer platform. Privately-held, Relypsa’s investors include: OrbiMed, 5AM Ventures, Delphi Ventures, Mediphase Venture Partners, New Leaf Venture Partners, Sprout Group, Amgen and Sibling Capital.

May 15, 2013 NEW
Relypsa Announces Appointment of John Orwin as Chief Executive Officer


May 13, 2013
Relypsa Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia